Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia

다국어 초록 (Multilingual Abstract)

Purpose: Combination therapy of a-blockers and 5α-reductase inhibitors (5-ARIs) is widely used for the treatment of benign prostatic hyperplasia (BPH). We aimed to study the effect on prostate volume and symptoms of shifting to monotherapy in patients who previously received a combination therapy.
Materials and Methods: A prospective study was conducted of 60 patients who were diagnosed with BPH. Patients were aged 45 years or older and had a prostate volume of 30 cc or more, International Prostate Symptom Score (IPSS) of 12 or above, maximal flow rate (Qmax) of 15 ml/s or less, and prostate-specific antigen (PSA) level of less than 10 ng/ml. The patients initially received a combination therapy of doxazosin 4 mg/day and finasteride 5 mg/day for 3 months and were then randomly assigned to receive monotherapy for 3 months. The factors were then compared.
Results: A total of 30 patients were assigned to doxazosin (group 1) and 30 to finasteride (group 2) after the combination therapy. The percentage changes in prostate volume, IPSS, and Qmax during the period from post-combination therapy to post-monotherapy were not significantly different between the two groups (p=0.052, 0.908, 0.081), whereas PSA significantly decreased in group 2 (p＜0.001). IPSS was not significantly different at post-combination therapy and at post-monotherapy in both groups (p=0.858, 0.071). The prostate volume significantly increased from 40.97 cc at post-combination therapy to 44.29 cc at post-monotherapy in group 1 (p=0.001) and insignificantly increased from 38.32 cc to 38.61 cc in group 2 (p=0.696).
Conclusions: Although the duration of drug administration was short in this study, 5-ARI monotherapy could maintain the alleviated symptoms and reduce the risk of acute urinary retention and surgery due to prostate regrowth in BPH patients whose symptoms improved with combination therapy.

참고문헌 (Reference)

1 소병현, "전립선비대증 환자에서α-차단제 및 Finasteride 병용치료에 따른 PSA의 변화 양상: 3년간 추적관찰 결과" 대한비뇨기과학회 47 (47): 372-376, 2006

2 Holtgrewe HL, "Transurethral prostatectomy: practice aspects of the dominant operation in American urology" 141 : 248-253, 1989

3 McConnell JD, "The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia" 349 : 2387-2398, 2003

4 Lepor H, "The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group" 335 : 533-539, 1996

5 McConnell JD, "The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group" 338 : 557-563, 1998

6 Gormley GJ, "The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group" 327 : 1185-1191, 1992

7 Stoner E, "The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group" 147 : 1298-1302, 1992

8 Roehrborn CG, "Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial" 50 : 556-561, 1997

9 홍경표, "Prospective Factor Analysis of Alpha Blocker Monotherapy Failure in Benign Prostatic Hyperplasia" 대한비뇨기과학회 51 (51): 488-491, 2010

10 Logan YT, "Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia" 3 : 103-114, 2005

11 Djavan B, "Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years" 64 : 1144-1148, 2004

12 de la Rosette JJ, "Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms" 167 : 1734-1739, 2002

13 Kim CI, "Long-term results of medical treatment in benign prostatic hyperplasia" ELSEVIER SCIENCE INC 68 : 1015-1015~1019, 2006

14 Lowe FC, "Goals for benign prostatic hyperplasia therapy" 59 (59): 1-2, 2002

15 Nickel JC, "Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers" 2 : 16-21, 2008

16 Kirby RS, "Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The prospective european doxazosin and combination therapy (PREDICT) trial" 61 : 119-126, 2003

17 Guess HA, "Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial" 20 : 627-636, 1993

18 Brawer MK, "Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359" 39 : 234-239, 1999

19 Jeong YB, "Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study" 73 : 802-806, 2009

20 Baldwin KC, "Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia" 58 : 203-209, 2001

21 Baldwin KC, "Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction" 66 : 84-88, 2001

22 Glassman DT, "Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia" 46 : 45-51, 2001

23 Emberton M, "Benign prostatic hyperplasia: a progressive disease of aging men" 61 : 267-273, 2003

24 Barkin J, "Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride" 44 : 461-466, 2003

25 Caine M, "Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy" 32 (32): 16-20, 1988

26 AUA Practice Guidelines Committee, "AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations" 170 : 530-547, 2003

27 Caine M, "A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction" 50 : 551-554, 1978